Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/23101
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pilgrim, Charles H C | - |
dc.contributor.author | Te Marvelde, Luc | - |
dc.contributor.author | Stuart, Ella | - |
dc.contributor.author | Croagh, Dan | - |
dc.contributor.author | Deutscher, David | - |
dc.contributor.author | Nikfarjam, Mehrdad | - |
dc.contributor.author | Lee, Belinda | - |
dc.contributor.author | Christophi, Christopher | - |
dc.date | 2020-04-29 | - |
dc.date.accessioned | 2020-05-05T23:59:24Z | - |
dc.date.available | 2020-05-05T23:59:24Z | - |
dc.date.issued | 2020-04-29 | - |
dc.identifier.citation | ANZ Journal of Surgery 2020; online first: 29 April | - |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/23101 | - |
dc.description.abstract | The Victorian Pancreas Cancer summit 2017 analysed state-wide data on management of Victorians with pancreas cancer between 2011 and 2015 to identify variations in care and outcomes. Pancreas cancer remains a formidable disease but systemic therapies are increasingly effective. Surgery remains essential but insufficient alone for cure. Understanding patterns of care and identifying variations in treatment is critical to improving outcomes. This population-based study analysed data collected prospectively by Department of Health and Human services (Victorian state government). Data were extracted from Victorian Cancer Registry (covering all Victorian cancer diagnoses), Victorian Admitted-Episodes Dataset (all inpatient data), Victorian Radiotherapy Minimum Dataset and Victorian Death Index providing demographics, tumour and treatment characteristics, age-standardized incidence, overall and median survival. Of 3962 Victorian patients with any form of pancreatic malignancy, 82% were ductal adenocarcinoma (PDAC), of whom 67% had metastases at diagnosis. One-year overall survival for PDAC was 30% (60% non-metastatic, 15% if metastatic). Median survival with metastases increased from 2.7 to 3.9 months, and from 13.3 to 15.9 months for non-metastatic PDAC between 2011 and 2015. Thirty-one percent of non-metastatic patients underwent pancreatectomy. About 1.5% were treated with neoadjuvant chemotherapy/chemoradiation. Of patients undergoing intended curative resection, 77% proceeded to adjuvant therapy. Fifty-one percent of metastatic PDAC patients never received anti-tumour therapy. Nearly one-fourth of surgically treated patients never received systemic therapy. More than two-thirds of non-metastatic patients never proceeded to surgery. Further consideration of neoadjuvant therapy should be given to borderline resectable patients. Most patients with PDAC still die soon after diagnosis, but median survival is increasing. | - |
dc.language.iso | eng | - |
dc.subject | hepatopancreaticobiliary surgery | - |
dc.subject | pancreas | - |
dc.subject | surgical oncology | - |
dc.title | Population-based analysis of treatment patterns and outcomes for pancreas cancer in Victoria. | - |
dc.type | Journal Article | - |
dc.identifier.journaltitle | ANZ Journal of Surgery | - |
dc.identifier.affiliation | Cabrini Medical Centre, Melbourne, Victoria, Australia | en |
dc.identifier.affiliation | Cancer Epidemiology & Intelligence Division, Cancer Council Victoria, Melbourne, Victoria, Australia | en |
dc.identifier.affiliation | Cancer Strategy & Development, Department of Health and Human Services, Melbourne, Victoria, Australia | en |
dc.identifier.affiliation | Hepatopancreaticobiliary Surgery, The Alfred Hospital, Melbourne, Victoria, Australia | en |
dc.identifier.affiliation | Department of Surgery, Austin Health, Heidelberg, Victoria, Australia | en |
dc.identifier.affiliation | Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia | en |
dc.identifier.affiliation | Walter and Eliza Hall Institute, University of Melbourne, Melbourne, Victoria, Australia | en |
dc.identifier.affiliation | Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia | en |
dc.identifier.affiliation | Melbourne Health, Melbourne, Victoria, Australia | en |
dc.identifier.affiliation | Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia | en |
dc.identifier.affiliation | Department of Surgery, Ballarat Health Services, Ballarat, Victoria, Australia | en |
dc.identifier.affiliation | Department of Surgery, Monash University, Melbourne, Victoria, Australia | en |
dc.identifier.affiliation | Monash Health, Melbourne, Victoria, Australia | en |
dc.identifier.affiliation | Epworth Healthcare, Melbourne, Victoria, Australia | en |
dc.identifier.doi | 10.1111/ans.15721 | - |
dc.identifier.orcid | 0000-0003-2193-7305 | - |
dc.identifier.orcid | 0000-0003-4866-276X | - |
dc.identifier.pubmedid | 32347639 | - |
dc.type.austin | Journal Article | - |
local.name.researcher | Christophi, Christopher | |
item.languageiso639-1 | en | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.openairetype | Journal Article | - |
crisitem.author.dept | Surgery (University of Melbourne) | - |
crisitem.author.dept | Surgery | - |
crisitem.author.dept | Hepatopancreatobiliary Surgery | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.